

### **Provider alert**

Blue Cross commercial Category: Pharmacy Publication start date: May 27, 2021 Publication end date: Oct. 7, 2021

# Four additional drugs to require prior authorization for Blue Cross URMBT non-Medicare members, for dates of service on or after Sept. 7

For dates of service on or after Sept. 7, 2021, four additional drugs will require prior authorization when administered in an outpatient setting for Blue Cross UAW Retiree Medical Benefits Trust, or URMBT, non-Medicare members.

Two of these drugs will also be subject to site-of-care requirements and waste avoidance quantity limits.

All of these drugs are covered under the medical benefit.

Refer to the table below for the details.

	Other requirements		
Drug	Site of care	Waste avoidance	How to submit prior authorization requests
Crysvita <sup>®</sup> (burosumab), HCPCS code J0584	Yes	No	Submit prior authorization requests through NovoLogix. It offers real-time status checks and immediate approvals for certain medications. To learn how to submit requests through NovoLogix, do the following: 1. Go to ereferrals.bcbsm.com.
Luxturna <sup>®</sup> (voretigene neparvovec), HCPCS code J3398	No	No	
Ultomiris <sup>®</sup> (ravulizumab), HCPCS code J1303	Yes	Yes	<ol> <li>Click <i>Blue Cross.</i></li> <li>Click <u>Medical Benefit Drugs</u>.</li> <li>Scroll to the Blue Cross commercial column.</li> <li>Review the information in the "How to submit authorization requests electronically using NovoLogix" section.</li> </ol>
Poteligeo <sup>®</sup> (mogamulizumab), HCPCS code J9204	No	No	<ul> <li>Submit prior authorization requests to AIM using one of the following methods:</li> <li>Through the <u>AIM ProviderPortal</u>*</li> <li>By calling the AIM Contact Center at 1-844-377-1278</li> <li>For information about registering for and accessing the AIM ProviderPortal, see the <u>Frequently asked questions page*</u> on the AIM website.</li> </ul>



## **Provider alert**

Blue Cross commercial Category: Pharmacy Publication start date: May 27, 2021 Publication end date: Oct. 7, 2021

#### **Explanation of other requirements**

Through site-of-care requirements, members receiving select injectable or infusible drugs in the outpatient hospital setting are redirected to a lower cost, alternate site of care, such as the physician's office or member's home.

Through the waste avoidance program, dosing limits for these drugs will be based on weight and will be specific to:

- The dosing guidelines of the U. S. Food and Drug Administration and the manufacturer
- Current medical best practices

#### More about the authorization requirements

Authorization isn't a guarantee of payment. As always, health care practitioners need to verify eligibility and benefits for members.

For additional information on requirements related to drugs covered under the medical benefit for Blue Cross URMBT non-Medicare members, see:

- <u>Medical oncology prior authorization list for UAW Retiree Medical Benefits Trust</u>
   <u>PPO non-Medicare members</u>
- <u>Medical Drug Management with Blue Cross for UAW Retiree Medical Benefit Trust</u>
   <u>PPO non-Medicare Members</u>

Note: Accredo manages prior authorization requests for additional medical benefit drugs.

We'll update the appropriate drug lists to reflect the information in this message prior to the effective date.

\*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.